RxDoctor Payments Data

Wai Bong

Medical · Flushing, NYNPI 1184020315

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by AbbVie at 54.5% of the total. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,933in general payments, 2019–2025

Across 844 payments — averaging $73.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$34K
  • IBSA Pharma Inc.$6K
  • Amgen$5K
  • AstraZeneca$3K
  • Gilead$2K
  • Novo Nordisk$2K
  • plus $11K from 38 others

What the payments were for

  • Consulting fees$4,5257%
  • Speaking & faculty fees$25,95042%
  • Travel & lodging$1090%
  • Food & beverage$31,13150%
  • Education$2180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,933 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl352$179,016
CreonLipase/Protease/Amylase60$177,829
Diclofenac Epolamine175$129,209
Budesonide ErBudesonide41$89,582
LinzessLinaclotide143$81,833
Diclofenac Sodium192$69,919
VemlidyTenofovir Alafenamide31$44,574
EliquisApixaban46$42,092
FarxigaDapagliflozin Propanediol65$40,818
RybelsusSemaglutide34$37,462
JardianceEmpagliflozin49$37,377
Evenity (2 Syringes)Romosozumab-Aqqg15$36,816
OzempicSemaglutide36$35,108
JanuviaSitagliptin Phosphate49$34,056
Metformin Er GastricMetformin Hcl18$28,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Ubrelvy, Restasis$33,756$306,303253 claims
Novo NordiskRybelsus, Ozempic$1,570$72,57070 claims
PfizerEliquis, Retacrit$96$61,83561 claims
AmgenEvenity (2 Syringes), Prolia$5,117$59,44328 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$1,111$52,38180 claims
MerckJanuvia, Janumet$537$49,43568 claims
GileadVemlidy$1,630$44,57431 claims
AstraZenecaFarxiga$2,619$40,81865 claims
Johnson & JohnsonXarelto$464$26,80951 claims
Ardelyx, Inc.Ibsrela$804$24,87114 claims
IBSA Pharma Inc.Licart$5,925$22,91630 claims
GSKTrelegy Ellipta, Shingrix$301$12,69833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.

Other medical in Flushing

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →